1. Home
  2. CQP vs NTRA Comparison

CQP vs NTRA Comparison

Compare CQP & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cheniere Energy Partners LP

CQP

Cheniere Energy Partners LP

HOLD

Current Price

$63.53

Market Cap

30.3B

Sector

Utilities

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$203.45

Market Cap

28.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CQP
NTRA
Founded
2003
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.3B
28.2B
IPO Year
2006
2015

Fundamental Metrics

Financial Performance
Metric
CQP
NTRA
Price
$63.53
$203.45
Analyst Decision
Sell
Strong Buy
Analyst Count
7
15
Target Price
$60.43
$259.07
AVG Volume (30 Days)
69.2K
1.5M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
5.05%
N/A
EPS Growth
N/A
0.65
EPS
0.07
N/A
Revenue
$10,758,000,000.00
$210,939,000.00
Revenue This Year
$6.35
$18.08
Revenue Next Year
$1.27
$19.65
P/E Ratio
$924.86
N/A
Revenue Growth
23.60
N/A
52 Week Low
$49.53
$131.81
52 Week High
$70.64
$256.36

Technical Indicators

Market Signals
Indicator
CQP
NTRA
Relative Strength Index (RSI) 48.22 50.89
Support Level $61.40 $186.96
Resistance Level $67.73 $204.34
Average True Range (ATR) 1.71 10.78
MACD 0.03 0.10
Stochastic Oscillator 46.73 49.78

Price Performance

Historical Comparison
CQP
NTRA

About CQP Cheniere Energy Partners LP

Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The profit generated through those activities is split with parent and operator Cheniere Energy.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: